BioSpace News Archive

VBL Therapeutics, announced that the European Patent Office has granted Patent #3328401, which covers VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat oncology conditions.

Altimmune, Inc., a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for liver disease, announced that management will present at the following upcoming virtual investor conferences

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that the first participant was enrolled in the observational PRECISION study, to examine the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic.

Clinically meaningful, dose-dependent, and statistically significant improvements in theCognitive Drug Research(CDR) computerized assessmentsystem analysis

Approval Based on Significant Overall Survival Findings from Phase 3 KEYNOTE-048 Trial

Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, announced that the U.S. Food and Drug Administration has granted orphan drug designation status to APX005M for the treatment of esophageal and gastroesophageal junction cancer and for the treatment of pancreatic cancer.

Lysogene, a Phase 3 gene therapy platform company targeting central nervous system diseases, announced that a patient has passed away in the AAVance clinical trial, a global Phase 2/3 gene therapy trial for the treatment of Mucopolysaccharidosis Type IIIA.

BioInvent International AB announce that they will be presenting a poster on BI-1808, an antibody to tumor necrosis factor receptor 2, at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting.

First human adenovirus (hAd5) vector vaccine candidate to deliver both outer spike (S) and inner nucleocapsid (N) antigens from SARS-CoV-2, offering potential long-term T cell and antibody immunity to the SARS-CoV-2 virus

Reata Pharmaceuticals, Inc. announced the upcoming presentation of KIDNEYCODE: A Genetic Testing Program for Patients with Chronic Kidney Disease, as an e-poster to be presented at the American Society of Nephrology Kidney Week 2020 Reimagined.